Detalhe da pesquisa
1.
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
Int J Cancer
; 154(9): 1607-1615, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38196128
2.
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 545-550, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38517658
3.
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.
Int J Clin Oncol
; 29(5): 535-544, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38494578
4.
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(4): 355-362, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38353907
5.
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38649648
6.
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005).
Lung
; 202(1): 63-72, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38265672
7.
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 551-558, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38526621
8.
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 559-563, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538963
9.
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 2024 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38578596
10.
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38696053
11.
Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
Cancer Sci
; 114(11): 4343-4354, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37715310
12.
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Eur Respir J
; 60(6)2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35361630
13.
Identification of targetable kinases in idiopathic pulmonary fibrosis.
Respir Res
; 23(1): 20, 2022 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35130915
14.
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
Int J Clin Oncol
; 27(1): 112-120, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34643820
15.
Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801.
Int J Clin Oncol
; 27(7): 1139-1144, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35534642
16.
COVID-19 Vaccine-Associated Lymphadenopathy Mimicking Regrowth of Axillary Lymph Node Metastasis of Lung Adenocarcinoma.
Acta Med Okayama
; 76(5): 593-596, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36352807
17.
Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.
Cancer Sci
; 112(8): 3255-3265, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34036692
18.
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Cancer Sci
; 112(5): 1853-1864, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33410241
19.
Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.
Cancer Immunol Immunother
; 70(1): 101-106, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32648165
20.
A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
Jpn J Clin Oncol
; 51(6): 956-965, 2021 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-33829270